Mazindol

DRUG3 trials

Sponsors

Yale University, NLS Pharmaceutics

Conditions

Attention Deficit Disorder With HyperactivityCocaine-Related DisordersNarcolepsyNarcolepsy With CataplexyNarcolepsy Without Cataplexy

Phase 2

Mazindol for Cocaine Abuse - 2

CompletedNCT00000277

Yale UniversityCocaine-Related Disorders

Start: 1994-09-30End: 1999-08-31Updated: 2020-06-18

Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

CompletedNCT02808104

NLS PharmaceuticsAttention Deficit Disorder With Hyperactivity

Start: 2016-08-31End: 2017-03-28Updated: 2017-04-06

An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy

CompletedNCT05055024

NLS PharmaceuticsNarcolepsy, Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy

Start: 2021-10-26End: 2023-01-19Updated: 2023-03-13

Related Papers

A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)

CNS Drugs2018-03-0126 citations